Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression

Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in... Ann Hematol (2010) 89:97–99 DOI 10.1007/s00277-009-0769-8 LETTER TO THE EDITOR Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression Yu-Yan Hwang & Kai Y. Wong & Rock Y. Y. Leung & Simon H. M. Wong & See-Ching Chan & Gopesh Srivastava & Wing Y. Au Received: 21 May 2009 /Accepted: 26 May 2009 /Published online: 9 June 2009 # Springer-Verlag 2009 Dear Editor, λ-chain, but not CD10, CD20, CD34, and FMC-7. There A 53-year-old woman, with cadaveric liver transplant for was spontaneous tumor lysis (lactate dehydrogenase primary biliary cirrhosis 7 years ago, presented with 4,760 IU/ml, normal 200–360; urate 1,120 mmol/l, normal generalized lymphadenopathy (Fig. 1a). A biopsy showed 160–380), accompanied by an upsurge in circulating EBV- post-transplantation lymphoproliferative disease (PTLD; DNA and a new monoclonal band (IgMκ 4.6 g/l). She was Fig. 1b). The lymphoma cells expressed CD20, CD79a, treated with COMP×4 (cyclophosphamide, vincristine, κ-chain, and Epstein Barr virus-encoded RNA (EBER). Her methotrexate, and prednisolone). Tacrolimus was continued bone marrow examination was normal but a serum but she died of isolated brain relapse 6 months later. immunoelectrophoresis showed a monoclonal protein The two EBV-related lesions had different morphology, (IgGλ 8.2 g/l). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression

Download PDF
3 pages

Loading next page...
 
/lp/springer-journal/post-rituximab-burkitt-transformation-of-ptld-loss-of-cd20-expression-MNrAcgsQxi

References (7)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer-Verlag
Subject
Medicine & Public Health; Oncology ; Hematology
ISSN
0939-5555
eISSN
1432-0584
DOI
10.1007/s00277-009-0769-8
pmid
19506869
Publisher site
See Article on Publisher Site

Abstract

Ann Hematol (2010) 89:97–99 DOI 10.1007/s00277-009-0769-8 LETTER TO THE EDITOR Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression Yu-Yan Hwang & Kai Y. Wong & Rock Y. Y. Leung & Simon H. M. Wong & See-Ching Chan & Gopesh Srivastava & Wing Y. Au Received: 21 May 2009 /Accepted: 26 May 2009 /Published online: 9 June 2009 # Springer-Verlag 2009 Dear Editor, λ-chain, but not CD10, CD20, CD34, and FMC-7. There A 53-year-old woman, with cadaveric liver transplant for was spontaneous tumor lysis (lactate dehydrogenase primary biliary cirrhosis 7 years ago, presented with 4,760 IU/ml, normal 200–360; urate 1,120 mmol/l, normal generalized lymphadenopathy (Fig. 1a). A biopsy showed 160–380), accompanied by an upsurge in circulating EBV- post-transplantation lymphoproliferative disease (PTLD; DNA and a new monoclonal band (IgMκ 4.6 g/l). She was Fig. 1b). The lymphoma cells expressed CD20, CD79a, treated with COMP×4 (cyclophosphamide, vincristine, κ-chain, and Epstein Barr virus-encoded RNA (EBER). Her methotrexate, and prednisolone). Tacrolimus was continued bone marrow examination was normal but a serum but she died of isolated brain relapse 6 months later. immunoelectrophoresis showed a monoclonal protein The two EBV-related lesions had different morphology, (IgGλ 8.2 g/l).

Journal

Annals of Hematology – Springer Journals

Published: Jan 1, 2010

There are no references for this article.